跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
獎項
活動
新聞/媒體
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
史 麗珠
特聘教授
,
公衛學科
特聘教授
,
分子醫學研究中心
https://orcid.org/0000-0002-1379-8969
電子郵件
D000000104
cgu.edu
tw
h-index
h10-index
h5-index
10246
引文
60
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
3430
引文
29
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
503
引文
14
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
1986 …
2024
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(41)
研究產出
(500)
相近領域學者
(12)
指導學生論文
(12)
指紋
查看啟用 Lai-Chu See 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Patient
100%
Inpatient
40%
Cohort Analysis
31%
Child
21%
Incidence
20%
Therapeutic Procedure
19%
Diagnosis
18%
Mortality
17%
Follow up
17%
Malignant Neoplasm
16%
Age
16%
Hazard Ratio
16%
Health
14%
Cohort Effect
12%
Analysis
12%
Survival
11%
Family
11%
Atrial Fibrillation
11%
Population Research
11%
Association
10%
Gout
10%
Prevalence
10%
Serum
10%
Cataract Surgery
9%
Hospital
9%
Combination Therapy
9%
Cardiovascular Disease
9%
Death
9%
Patient with Type 2 Diabetes
8%
Cardiovascular System
8%
Diabetes Mellitus
7%
Nasopharynx Carcinoma
7%
Lesion
7%
Hyperuricemia
7%
Person
7%
Surgery
7%
Adult
7%
Magnetic Resonance Imaging
7%
Adolescent
7%
Acute Heart Infarction
7%
Mortality Rate
7%
Cervical Cancer
6%
All Cause Mortality
6%
Systemic Lupus Erythematosus
6%
Neoplasm
6%
Positron Emission Tomography
6%
Woman
6%
Dipeptidyl Peptidase-4 Inhibitor
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Male
6%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
31%
Cohort Study
27%
Anticoagulant Agent
21%
Warfarin
20%
Mortality
11%
Bleeding
10%
Dabigatran
10%
Incidence
9%
Antivitamin K
9%
Diabetes Mellitus
9%
Rivaroxaban
9%
Malignant Neoplasm
8%
Hyperuricemia
7%
Chronic Kidney Failure
7%
Brain Ischemia
7%
Non Insulin Dependent Diabetes Mellitus
7%
Cardiovascular Disease
6%
End Stage Renal Disease
6%
Acute Heart Infarction
5%
Mortality Rate
5%
Death
5%
Apixaban
5%
Dipeptidyl Peptidase IV Inhibitor
5%
Rheumatoid Arthritis
5%
Direct Oral Anticoagulant
5%
Nursing and Health Professions
Incidence
18%
Gout
15%
Confidence Interval
15%
Cohort Analysis
13%
Prevalence
13%
Patient
12%
Mortality
10%
Validity
9%
Hospital
9%
National Health Insurance
8%
Epidemiology
8%
Time
8%
Data Base
8%
Reliability
7%
Control
7%
Evaluation Study
7%
Pediatrics
6%
Athletes
6%
Hyperuricemia
6%
Reaction Time
6%
Diagnosis
6%
Rheumatoid Arthritis
6%
Malignant Neoplasm
5%
Inpatient
5%
Follow up
5%
Mortality Rate
5%
Survival
5%
Death
5%
Hazard Ratio
5%